Syntaxin 6, a regulator of the protein trafficking machinery and a target of the p53 family, is required for cell adhesion and survival.
The p53 family consists of p53, p63, and p73. It has been well characterized that all of the p53 family proteins are transcription factors and capable of regulating cell cycle and apoptosis. To determine whether the p53 family exerts tumor suppression by other mechanisms, we set to identify novel p53 family target genes. Here, we found that the gene encoding STX6 (syntaxin 6), a vesicle transporter protein, is directly regulated by each of the p53 family proteins. In addition, STX6 can be induced by DNA damage and Mdm2 inhibitor Nutlin-3 in a p53-dependent manner. To examine how STX6 mediates the activity of the p53 family, STX6 is inducibly overexpressed or knocked down in various cell lines. We found that overexpression of STX6 alone has limited effect on cell proliferation. In contrast, we found that knockdown of STX6 inhibits cell proliferation and survival. We also found that knockdown of STX6 leads to cell cycle arrest and apoptosis. Interestingly, we found that p53 is necessary for STX6 knockdown-induced cell cycle arrest and apoptosis. Furthermore, we found that STX6 is necessary for proper expression of focal adhesion kinase and integrin alpha5 adhesion receptor. Consistent with this observation, STX6 knockdown inhibits cell adhesion. Together, we postulate that STX6 is an effector and a modulator of the p53 family in the regulation of cell adhesion and survival.
Zhang
Yanhong
Y
Center for Comparative Oncology, University of California, Davis, California 95616, USA.
Shu
Limin
L
Chen
Xinbin
X
D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D002453:Cell Cycle / Q000187:drug effects / Q000502:physiology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D004249:DNA Damage / Q000187:drug effects / Q000502:physiology; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D051417:Focal Adhesion Kinase 1 / Q000096:biosynthesis / Q000235:genetics; D055785:Gene Knockdown Techniques / Q000379:methods; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D039564:Integrin alphaV / Q000235:genetics / Q000378:metabolism; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism*; D010879:Piperazines / Q000494:pharmacology; D021381:Protein Transport / Q000502:physiology; D051736:Proto-Oncogene Proteins c-mdm2 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D050765:Qa-SNARE Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D015534:Trans-Activators / Q000235:genetics / Q000378:metabolism*; D014157:Transcription Factors; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism*
D004268:DNA-Binding Proteins; D007093:Imidazoles; D039564:Integrin alphaV; D009687:Nuclear Proteins; D010879:Piperazines; D050765:Qa-SNARE Proteins; C000612950:STX6 protein, human; C495901:TP53 protein, human; C115051:TP63 protein, human; D015534:Trans-Activators; D014157:Transcription Factors; D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; C482205:nutlin 3; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; D051417:Focal Adhesion Kinase 1; C496050:PTK2 protein, human
Mol Cell Biol. 1994 Sep;14(9):5920-8
8065325
Mol Cell Biol. 2005 Mar;25(5):2014-30
15713654
J Biol Chem. 1996 Jul 26;271(30):17961-5
8663448
J Biol Chem. 2006 Mar 24;281(12):7856-62
16446369
Cell Mol Life Sci. 2004 Apr;61(7-8):822-42
15095006
J Cell Biol. 1996 Dec;135(5):1383-90
8947559
Cell Growth Differ. 1996 Apr;7(4):413-8
9052982
J Biol Chem. 2003 May 9;278(19):17557-65
12609999
Mol Biol Cell. 2001 Jun;12(6):1699-709
11408578
EMBO Rep. 2003 Jun;4(6):609-15
12776180
Mol Cell. 2008 Jan 18;29(1):9-22
18206965
J Cell Sci. 2003 Aug 15;116(Pt 16):3269-76
12857786
Mol Cell Biol. 2006 Feb;26(4):1398-413
16449651
Traffic. 2001 Sep;2(9):606-11
11555414
Science. 2002 Apr 19;296(5567):550-3
11910072
Neurosci Lett. 2008 May 16;436(3):340-4
18406529
J Cell Biol. 2004 Nov 22;167(4):745-56
15557124
Mol Biol Cell. 2003 Jul;14(7):2946-58
12857877
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):9011-6
12853575
J Biol Chem. 2002 Jul 26;277(30):27393-400
12011046
J Cell Biochem. 2006 Sep 1;99(1):35-52
16823799
J Biol Chem. 2005 Jul 1;280(26):25008-21
15855171
Cancer Res. 2007 Oct 1;67(19):9117-24
17909016
J Biol Chem. 2001 Jun 8;276(23):19820-7
11278762
Cancer Res. 1995 Nov 15;55(22):5187-90
7585571
Science. 2004 Feb 6;303(5659):844-8
14704432
Traffic. 2008 Jul;9(7):1173-90
18435821
Mol Cell. 2006 Nov 17;24(4):593-602
17188034
Methods Mol Biol. 2003;223:221-35
12777734
Curr Cancer Drug Targets. 2005 Dec;5(8):629-43
16375667
J Biol Chem. 2000 Dec 22;275(51):39927-34
10982799
Nature. 2001 Feb 15;409(6822):839-41
11237004
Mol Biol Cell. 2004 Apr;15(4):1690-701
14742717
Nat Cell Biol. 2006 Apr;8(4):317-28
16565709
J Cell Biol. 1998 Oct 19;143(2):547-60
9786962
J Clin Invest. 1999 Aug;104(3):263-9
10430607
Nat Cell Biol. 2006 Jun;8(6):551-61
16715076
J Cell Sci. 2008 Apr 15;121(Pt 8):1243-51
18388312
J Biol Chem. 2008 Feb 1;283(5):2896-905
18025081
Oncogene. 2003 Jul 10;22(28):4333-47
12853970
Curr Opin Cell Biol. 1997 Oct;9(5):701-6
9330874
Cancer Res. 1995 Oct 1;55(19):4257-63
7671232
Oncogene. 2005 Jan 27;24(5):761-79
15592521